Skip to content

Dr. Sappho Walravens

Active
Private limited companyfounded 2021active for 5 yearsZavelstraat 14, 1750 Lennik, BelgiumKBO/BCE: BE 0766.809.150

From the official registers: KBO 5 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

Dr. Sappho Walravens has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €87,575 and a net result of €79,706. Equity has been growing by about 14% per year since 2021. Its solvency ranks better than 90% of 20,678 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Risk analysisFollow ReportCompare
Dr. Sappho WalravensActiveChecked score 97/100
Risk analysis ReportCompare

Overview

Official details

KBO
Status
Active since 16-04-2021 Normal situation
Legal form
Private limited company
Registered office
Zavelstraat 14, 1750 Lennik
Activity
General medical practice NACE 86210
Establishment unit
2.316.321.002 1750 Lennik, since 16-04-2021
Financial year end
31 December
Peppol
Reachable since 28-12-2025
Company details

Board and ownership

Board
  • Walravens SapphoDirector · since 16-04-2021
Board & ownership

Financial position

97 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
< 0.1%
Annual accounts 2025
Gross margin
€104,993
▲ 10.7%
Turnover
≈ €190,000
estimated
Profit
€79,706
▲ 11.8%
Equity
€87,575
▲ 12.5%
Total assets
€93,264
▲ 8.8%
2025 accounts filed 12 days before the deadline
Filed on 19-07-2026at the National Bank
Financials
Score breakdownlowers riskSector: Human health activities (NACE 86)Liquidity: current ratio 16.19, cash €69,083Equity €87,575 (93.9% of total assets)Size: total assets €93,264Show the evidence

Checked score

Score 2025
97 / 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 78% of micro companies in human health (NACE 86)
Every signal that counts is listed under Signals.
Financial strength · tick: 2024
Strong
Solvency 100=
equity 93.9% of total assets
Liquidity 100=
short-term debt 6.1% · cash 74.1%
Profitability 100=
return on assets 85.5%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,155 companies, NACE 86, micro)
Last 24 months 11-2024: < 0.1% 12-2024: < 0.1%● unchanged vs 11-2024 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025 08-2025: < 0.1%● unchanged vs 07-2025highest value 09-2025: < 0.1%● unchanged vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: < 0.1%● unchanged vs 07-2026lowest value 09-2026: < 0.1%● unchanged vs 08-2026lowest value 10-2026: < 0.1%● unchanged vs 09-2026
Credit of up to €8,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 16.19 (10.59 in 2024), above the usual 1.5. Short-term debt is 6.1% and cash 74.1% of total assets. 6.1% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 82% of them on solvency, 95% on liquidity, 80% on profitability and 55% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskneutral
lowers risk · Sector: Human health activities (NACE 86)
KBO
lowers risk · Liquidity: current ratio 16.19, cash €69,083
NBB · annual accounts
lowers risk · Equity €87,575 (93.9% of total assets)
NBB · annual accounts
lowers risk · Size: total assets €93,264
Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 19-07-2026, 12 days ahead of the deadline.
NBB · 5 filings
Deviation from the deadline
2025
12 days early
2024
28 days late
2023
30 days late
2022
60 days late
2021
31 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 5 accounts on average 27 days after the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 31 August (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
01-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Key points

  • Positive: Higher solvency than 89% of companies in human healthsector median 63.0% · 20,678 companies 93.9% View
  • Positive: 5 profitable years in a rowprofit 2025: €79,706 5 years View

Documents

Annual accounts at the NBB

All 5 annual accounts

Acts in the Belgian Official Gazette

All publications in the Belgian Official Gazette

Articles and registers

Key facts about Dr. Sappho Walravens

What is the company number of Dr. Sappho Walravens?
The company number of Dr. Sappho Walravens is 0766.809.150. The VAT number is the same number with BE in front: BE 0766.809.150.
Where is Dr. Sappho Walravens based?
The registered office is at Zavelstraat 14, 1750 Lennik.Company details
What does Dr. Sappho Walravens do?
According to the KBO register, the main activity is general medical practice (NACE 86210).
What is the legal form of Dr. Sappho Walravens?
The legal form of Dr. Sappho Walravens is Private limited company (BV).
When was Dr. Sappho Walravens founded?
Dr. Sappho Walravens was founded on 16-04-2021.
Is Dr. Sappho Walravens still active?
Yes, Dr. Sappho Walravens is an active enterprise in the KBO register.
What is the turnover of Dr. Sappho Walravens?
The turnover in financial year 2025 is ≈ €190,000. This figure is estimated from the gross margin of €104,993 and 30 comparable companies (NACE 86210). It probably lies between €150,000 and €240,000.Financials
Is Dr. Sappho Walravens profitable?
In financial year 2025, Dr. Sappho Walravens made a profit of €79,706.
Where can I find the annual accounts of Dr. Sappho Walravens?
Dr. Sappho Walravens filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts at the National Bank
When are the next annual accounts of Dr. Sappho Walravens due?
Dr. Sappho Walravens must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Comparable companies

These companies have the same main activity as Dr. Sappho Walravens: general medical practice (NACE 86210). They are comparable in size and age: total assets between €80,400 and €96,200, founded between 2020 and 2021.

CompanyTotal assetsGross margin
Dr. Sappho Walravens Lennik€93,264€104,993
Dr. G. Dewolf Leuven€88,439€97,844
Huisarts Corneel Verburgh Huldenberg€80,559€98,931
Dr. Jolien Dirckx Leuven€80,434€99,857
Dokter Johan Vanden Bulcke Beveren-Kruibeke-Zwijndrecht€93,358€105,585
Dr. Mattijs Govaerts, huisarts Antwerpen€96,180€107,078
Medket Dilsen-Stokkem€85,452€107,414
Full comparison

Next steps

Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure